Vermillion sales and marketing update
Vermillion said its Aspira Inc. CLIA-certified reference lab is now operational. Aspira is providing diagnostic services, including OVA1 and Longitudinal CA 125 testing, to support clinical decision-making and advance personalized treatment plans. Aspira is located near Austin. OVA1 is an in vitro diagnostic multivariate index (IVDMIA) test based on Vermillion’s SELDI ProteinChip technology, which helps assess the likelihood that an ovarian mass is benign or malignant. For Longitudinal CA 125 testing, Vermillion said the CA 125 baseline level is obtained from OVA1 prior to initial surgery and diagnosis of ovarian cancer, after which the gynecologic oncologist can order a multi-point CA 125 graph comparing the baseline to a newly measured CA 125 result as part of postsurgical monitoring. The company also said the test report may help detect residual disease or ovarian cancer recurrence. ...